It has been reported that 7‐ethyl‐10‐[4‐(1‐piperidino)‐1‐piperidino] carbonyloxy‐
camptothecin (CPT‐11) and its active metabolite, 7‐ethyl‐10‐hydroxy‐camptothecin (SN …

The prevention of irinotecan (CPT-11)-induced diarrhea, a well-known adverse reaction to
the drug, by treatment with intestinal alkalinization has been carried out in patients with …

Diarrhea is one of dose-limiting factors of irinotecan (CPT-11) and its incidence is over 60%
in patients receiving this drug. Therefore, it is important to prevent diarrhea for more effective …

Purpose. To ameliorate the late-onset of severe gastrointestinal toxicity provoked by
irinotecan (CPT-11), which may be related to the biliary excretion of CPT-11 and/or its …

Abstract Irinotecan (CPT‐11) and its active metabolite, 7‐ethyl‐10‐hydroxycamptothecin
(SN‐38), are believed to be reabsorbed by intestinal cells and to enter the entero‐hepatic …

PURPOSE: The aim of this study was to investigate the excretion of irinotecan hydrochloride
(CPT-11) and its metabolites into the gastrointestinal lumen via the biliary route after …

Purpose It is well known that CPT-11 (irinotecan) is biotransformed to its active metabolite,
SN-38, by carboxylesterase in the liver and other tissues. However, little is known about its …

In clinical use, irinotecan hydrochloride (CPT‐11; 7‐ethyl‐10‐[4‐(piperidmo)‐l‐piperidino]
carbonyl‐oxycamptothecin), a novel antitumor agent, causes a relatively high incidence of …

Abstract Purpose: SN-38, a metabolite of irinotecan hydrochloride (CPT-11), is considered to
play a key role in the development of diarrhea as well as in the antitumor activity of CPT-11 …

Abstract Irinotecan (CPT-11) is a camptothecin analog with low (about 10-20%) and variable
oral bioavailability in animal models. Here, Caco-2 cells were used to evaluate the …